Unlocking the Potential of C4orf17: A novel CD017_HUMAN drug target and biomarker

Target Name: C4orf17

NCBI ID: G84103

C4orf17

Other Name(s): CD017_HUMAN | Chromosome 4 open reading frame 17 | chromosome 4 open reading frame 17 | Uncharacterized protein C4orf17

Unlocking the Potential of C4orf17: A novel CD017_HUMAN drug target and biomarker

Cancer is one of the leading causes of human mortality, with over 80% of all deaths due to cancer. The development of new treatments and biomarkers has become a critical focus in the fight against cancer. One of the promising candidates for cancer treatment is C4orf17 (CD017_HUMAN), a gene that has been identified as a potential drug target and biomarker for various types of cancer.

C4orf17: A novel gene associated with cancer

C4orf17, also known as CD017, is a gene that encodes a protein known as C4ORF17. The protein is expressed in various tissues and cells of the body and is involved in various cellular processes, including cell adhesion, migration, and invasion. C4ORF17 has also been shown to play a role in the development and progression of various types of cancer.

Recent studies have suggested that C4ORF17 may be a potential drug target for cancer treatment. By inhibiting the activity of C4ORF17, researchers have found that they can reduce the growth and spread of cancer cells. Additionally, studies have shown that targeting C4ORF17 with small molecules has the potential to be an effective cancer treatment.

C4orf17 as a biomarker

In addition to its potential as a drug target, C4ORF17 has also been identified as a potential biomarker for cancer. The expression of C4ORF17 has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that C4ORF17 may be a useful biomarker for the diagnosis and monitoring of cancer.

C4ORF17 has also been shown to be involved in the development of various types of cancer, including pre-malignant diseases. For example, studies have shown that C4ORF17 is involved in the development of colon cancer in both humans and animals. Additionally, C4ORF17 has also been shown to be involved in the development of skin cancer, as well as neurodegenerative diseases.

The potential implications of C4ORF17 as a biomarker for cancer are significant. By using C4ORF17 as a biomarker for cancer, researchers may be able to develop new diagnostic tests, as well as new treatments for cancer. Additionally, C4ORF17 may also be a useful biomarker for monitoring the effectiveness of cancer treatments and evaluating the effectiveness of new treatments.

Conclusion

C4orf17 is a gene that has been shown to play a role in the development and progression of various types of cancer. As a potential drug target and biomarker, C4orf17 has the potential to revolutionize the treatment of cancer. By inhibiting the activity of C4ORF17, researchers may be able to develop new treatments for cancer that are more effective and less invasive. Additionally, C4ORF17 may also be a useful biomarker for the diagnosis and monitoring of cancer. Further research is needed to fully understand the potential implications of C4ORF17 as a drug target and biomarker for cancer.

Protein Name: Chromosome 4 Open Reading Frame 17

The "C4orf17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C4orf17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets